Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Inclusion Criteria: * History of cardiovascular (CV) disease, high CV risk, or estimated glomerular filtration rate (eGFR) ≥30 to \<60 mL/min/1.73m\^2 * Mean seated office SBP ≥140 mmHg and ≤170 mmHg * 24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM * Must be on stable therapy with 2 to 4 classes of antihypertensive medications Exclusion Criteria: * Secondary hypertension * Orthostatic hypotension * Proteinuria \>3 g/day * Serum potassium \>4.8 milliequivalents per liter (mEq/L)